

# **Market Announcement**

31 January 2024

## Imricor Medical Systems, Inc. (ASX: IMR) - Trading Halt

### **Description**

The securities of Imricor Medical Systems, Inc. ('IMR') will be placed in trading halt at the request of IMR, pending it releasing an announcement. Unless ASX decides otherwise, the securities will remain in trading halt until the earlier of the commencement of normal trading on Friday, 2 February 2024 or when the announcement is released to the market.

#### **Issued by**

**ASX Compliance** 



31 January 2024

Melissa Kostopoulos Senior Adviser, Listings Compliance (Melbourne) South Tower, Level 50, 525 Collins Street Melbourne VIC 3000

By email only: <a href="mailto:melissa.kostopoulos@asx.com.au">melissa.kostopoulos@asx.com.au</a>; <a href="mailto:tradinghaltsmelbourne@asx.com.au">tradinghaltsmelbourne@asx.com.au</a>;

Dear Ms Kostopoulos

#### REQUEST FOR TRADING HALT

Imricor Medical Systems, Inc. (ASX: **IMR**) (the **Company**) requests an immediate halt to the trading of the Company's CHESS Depositary Instruments (CDIs) quoted on the Australian Securities Exchange (**ASX**) in accordance with ASX Listing Rule 17.1.

The trading halt is requested pending an announcement to be made by the Company to the market in relation to an update in connection with a proposed capital raising.

In accordance with Listing Rule 17.1, the Company provides the following information in relation to the request:

- The trading halt is necessary to assist the Company in managing its continuous disclosure obligations as the Company expects to make a material announcement to the market in relation to a proposed capital raising.
- 2. The Company requests that the trading halt remains in place until the earlier of commencement of normal trading on Friday, 2 February 2024, or when the announcement regarding the proposed capital raising is released.
- 3. The Company expects to make the announcement to the market before the commencement of normal trading on Friday, 2 February 2024.
- 4. The Company is not aware of any reason why the trading halt should not be granted or of any further information necessary to inform the market about the trading halt.

Please contact me if you require any further information concerning this matter.

Yours sincerely

By order of the Board of Imricor Medical Systems, Inc.

Kobe Li Company Secretary